Quantitative PCR (qPCR) enables precise, quantitative targeted gene expression measurements, delivering key results for actionable genomic alteration analysis.
Our scientists are experts in providing qPCR services – whether they’re running off-the-shelf (OTS) assays or designing custom primer/probe sets for actionable genomic alteration detection (AGAs).
As the gold standard for nucleic acid quantification, our qPCR studies are a versatile tool for any clinical study, aiding in therapeutic development, as well as patient selection and management.
Our laboratories have processed tens of thousands of clinical samples for quantification, making us the ideal partner to handle your qPCR workflow.
CellCarta can support any qPCR-based application, with experience running key OTS assays for AGA assessment. Our portfolio includes:
Download our brochure for more details on the genomics assays available at CellCarta.
Our team has expertise in the design and validation of custom primers/probe sets and overall assay design for AGA detection. Our solutions will fully support qPCR studies from discovery and exploration all the way through to patient management and CDx.
With access to over 5000 validated, phenotype-characterized samples, our team can reduce assay development timelines by 4-6 weeks, accelerating your research progress.
Contact us about any custom developments.
Our team has proficiency on several key platforms for the high-throughput and rigorous testing of clinical samples, including:
Our platforms are validated for all biological matrices, including both tissue and liquid biopsies.
With experience performing qPCR on tens of thousands of samples, our workflows can handle high-throughput processing with ease.
CellCarta can support any qPCR-based application, with experience running key OTS assays for AGA assessment. Our portfolio includes:
Download our brochure for more details on the genomics assays available at CellCarta.
Our team has expertise in the design and validation of custom primers/probe sets and overall assay design for AGA detection. Our solutions will fully support qPCR studies from discovery and exploration all the way through to patient management and CDx.
With access to over 5000 validated, phenotype-characterized samples, our team can reduce assay development timelines by 4-6 weeks, accelerating your research progress.
Contact us about any custom developments.
Our team has proficiency on several key platforms for the high-throughput and rigorous testing of clinical samples, including:
Our platforms are validated for all biological matrices, including both tissue and liquid biopsies.
With experience performing qPCR on tens of thousands of samples, our workflows can handle high-throughput processing with ease.
CellCarta is the global exclusive provider of Biofidelity’s Aspyre® Lung in clinical trial settings, a multi-gene profiling panel designed to run on existing qPCR platforms. Aspyre simplifies the detection of NSCLC biomarkers for a fast turnaround in results, streamlining patient management.
Streamline your study by integrating our qPCR services — validated for any clinical endpoint.
Deep Scientific Rigor
Easy Clinical Implementation
Global Execution
Cutting-edge Technologies
High-throughput Processing
Combine our qPCR services with our other genomics offerings to get a complete understanding of your data.
In-depth genomics and transcriptomics data for your translational and clinical applications.
Nucleic acid quantification with superior accuracy, precision, and sensitivity.
Robust detection of key oncogenes, including EGFR, KRAS, BRAF, FGFR, and PI3KCA.
Quantitative PCR (qPCR) is a highly sensitive molecular technique used to detect and quantify nucleic acids — including DNA, mRNA, microRNA, and long non-coding RNA (lncRNA).
When combined with a reverse transcription step (RT-qPCR), it becomes the gold standard for targeted gene expression analysis. qPCR offers excellent sensitivity, specificity, and a wide linear dynamic range, making it well suited for both research and clinical trial applications.
Yes. CellCarta offers access to a broad menu of validated off-the-shelf (OTS) qPCR assays, including the AmoyDx Pan Lung Cancer Panel, Biofidelity Aspyre® Lung assay, Cobas mutation tests (EGFR, KRAS, BRAF V600, PIK3CA, BRAF/NRAS), and Qiagen Therascreen kits (EGFR, PIK3CA, KRAS, FGFR).
These widely accepted assays support patient selection and identification of druggable targets. View our genomic assay list for a complete overview.
CellCarta's qPCR services are equipped to process a broad range of sample types, including FFPE (formalin-fixed paraffin-embedded) tissue, liquid biopsies, whole blood, and cell lysates.
Our team has processed tens of thousands of clinical samples across these formats, with validated workflows designed to maintain data integrity even from challenging or limited-input specimens.
CellCarta operates multiple leading qPCR instrument platforms to ensure flexibility and fit-for-purpose analysis. Our team works with the cobas system (Roche), Rotor-Gene Q (Qiagen), Idylla (Biocartis), and QuantStudio (ThermoFisher).
This multi-platform infrastructure supports both off-the-shelf assays and custom-designed, validated workflows tailored to your study requirements.
